HK1159514A1 - Ht0712 for the treatment of a cognitive deficit ht0712 - Google Patents

Ht0712 for the treatment of a cognitive deficit ht0712

Info

Publication number
HK1159514A1
HK1159514A1 HK12100142.3A HK12100142A HK1159514A1 HK 1159514 A1 HK1159514 A1 HK 1159514A1 HK 12100142 A HK12100142 A HK 12100142A HK 1159514 A1 HK1159514 A1 HK 1159514A1
Authority
HK
Hong Kong
Prior art keywords
treatment
cognitive deficit
cognitive
rolipram
phosphodiesterase
Prior art date
Application number
HK12100142.3A
Other languages
English (en)
Chinese (zh)
Inventor
Timothy P Tully
Filippo Cavalieri
Original Assignee
Cold Spring Harbor Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Lab filed Critical Cold Spring Harbor Lab
Publication of HK1159514A1 publication Critical patent/HK1159514A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Inorganic Insulating Materials (AREA)
  • Electric Double-Layer Capacitors Or The Like (AREA)
  • Magnetic Ceramics (AREA)
HK12100142.3A 2003-04-08 2006-08-21 Ht0712 for the treatment of a cognitive deficit ht0712 HK1159514A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/410,508 US20040224316A1 (en) 2000-08-10 2003-04-08 Augmented cognitive training

Publications (1)

Publication Number Publication Date
HK1159514A1 true HK1159514A1 (en) 2012-08-03

Family

ID=37416211

Family Applications (2)

Application Number Title Priority Date Filing Date
HK12100142.3A HK1159514A1 (en) 2003-04-08 2006-08-21 Ht0712 for the treatment of a cognitive deficit ht0712
HK06109214.5A HK1087351A1 (en) 2003-04-08 2006-08-21 Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK06109214.5A HK1087351A1 (en) 2003-04-08 2006-08-21 Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit

Country Status (8)

Country Link
US (2) US20040224316A1 (ja)
EP (4) EP2116240B1 (ja)
JP (1) JP4833834B2 (ja)
AT (1) ATE556707T1 (ja)
CA (1) CA2521839C (ja)
ES (3) ES2403333T3 (ja)
HK (2) HK1159514A1 (ja)
WO (1) WO2004091609A2 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
EP1355669B1 (en) * 2000-08-10 2011-09-28 Cold Spring Harbor Laboratory Augmented cognitive training
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US8975216B2 (en) * 2006-03-30 2015-03-10 Pacific Biosciences Of California Articles having localized molecules disposed thereon and methods of producing same
ES2412481T3 (es) * 2006-05-19 2013-07-11 Dart Neuroscience Llc Inhibidores de la fosfodiesterasa 4 para la rehabilitación motora
GB0722769D0 (en) * 2007-11-21 2008-01-02 Biolipox Ab New compounds
AR065709A1 (es) * 2007-03-12 2009-06-24 Biolipox Ab Piperidinonas y composiciones farmaceuticas que las contienen usadas para el tratamiento de la inflamacion. procesos de obtencion.
KR20100017422A (ko) * 2007-05-15 2010-02-16 헬리콘 테라퓨틱스 인코퍼레이티드 작은 간섭 ＲＮＡ(ｓｉＲＮＡ)를 이용하여 기억 형성에 관여하는 유전자를 확인하는 방법
JP2010527375A (ja) * 2007-05-15 2010-08-12 ヘリコン セラピューティクス，インコーポレイテッド Ｇｐｒ１２の阻害による認知障害の治療方法
JP5049713B2 (ja) * 2007-09-14 2012-10-17 株式会社コナミデジタルエンタテインメント ゲームシステム並びにこれを構成するゲーム装置及び課題報知装置
EP2313098A4 (en) * 2008-07-18 2011-12-21 Dart Neuroscience Llc METHOD AND SYSTEMS FOR THE ASSESSMENT OF MEMORY-PROMOTING ACTIVE SUBSTANCES
WO2011114103A1 (en) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones for use as medicaments
US20150050626A1 (en) * 2013-03-15 2015-02-19 Dart Neuroscience, Llc Systems, Methods, and Software for Improving Cognitive and Motor Abilities
CA2942446A1 (en) * 2014-03-28 2015-10-01 Algiax Pharmaceuticals Gmbh Treatment of cognitive disorders
CN116963773A (zh) 2021-01-21 2023-10-27 浙江养生堂天然药物研究所有限公司 治疗肿瘤的组合物及方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5479508A (en) * 1991-05-22 1995-12-26 Zenith Electronics Corp. Method of operating a pay per view television system
US5547979A (en) * 1992-03-30 1996-08-20 Smithkline Beecham TNF inhibition
HU225869B1 (en) 1992-04-02 2007-11-28 Smithkline Beecham Corp Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them
US5681735A (en) 1992-04-10 1997-10-28 Fox Chase Cancer Center Transcription control element for increasing gene expression in myoblasts
AU3265695A (en) * 1994-08-29 1996-03-22 Yamanouchi Pharmaceutical Co., Ltd. Novel naphthyridine derivative and medicinal composition thereof
US5619249A (en) * 1994-09-14 1997-04-08 Time Warner Entertainment Company, L.P. Telecasting service for providing video programs on demand with an interactive interface for facilitating viewer selection of video programs
US5929223A (en) * 1994-10-07 1999-07-27 Cold Spring Harbor Laboratory Cloning and characterizing of genes associated with long-term memory
EP0781335A1 (en) 1994-10-07 1997-07-02 Cold Spring Harbor Laboratory Cloning and characterizing of genes associated with long-term memory
US5652749A (en) * 1995-02-03 1997-07-29 International Business Machines Corporation Apparatus and method for segmentation and time synchronization of the transmission of a multiple program multimedia data stream
US5793410A (en) * 1995-05-26 1998-08-11 Hyundai Electronics America Video pedestal network
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
WO1998022137A1 (en) * 1996-11-15 1998-05-28 The Kennedy Institute Of Rheumatology SUPPRESSION OF TNF α AND IL-12 IN THERAPY
ES2193508T3 (es) * 1997-01-15 2003-11-01 Altana Pharma Ag Ftalizinonas.
JP4979157B2 (ja) 1998-09-09 2012-07-18 バイオリポックス アーべー 置換されたγ−フェニル−Δ−ラクトンおよびそのアナログならびにこれらに関する使用
IT1303272B1 (it) 1998-10-29 2000-11-06 Zambon Spa Derivati triciclici inibitori della fosfodiesterasi 4
AU764005B2 (en) 1999-02-25 2003-08-07 Merck Frosst Canada & Co. PDE IV inhibiting compounds, compositions and methods of treatment
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
EP2258689A1 (en) 2000-03-16 2010-12-08 Biolipox AB Benzylated PDE4 inhibitors
EP1355669B1 (en) * 2000-08-10 2011-09-28 Cold Spring Harbor Laboratory Augmented cognitive training
ES2344411T3 (es) 2002-08-19 2010-08-26 Helicon Therapeutics, Inc. Metodos de escrutinio para potenciadores cognitivos.

Also Published As

Publication number Publication date
US8097647B2 (en) 2012-01-17
CA2521839A1 (en) 2004-10-28
WO2004091609A3 (en) 2007-08-16
HK1087351A1 (en) 2006-10-13
EP2156831B1 (en) 2013-02-27
US20060247252A1 (en) 2006-11-02
EP2156831A1 (en) 2010-02-24
EP2340831A1 (en) 2011-07-06
EP2116240A1 (en) 2009-11-11
ES2403333T3 (es) 2013-05-17
JP4833834B2 (ja) 2011-12-07
CA2521839C (en) 2014-08-05
JP2006524243A (ja) 2006-10-26
US20040224316A1 (en) 2004-11-11
ATE556707T1 (de) 2012-05-15
WO2004091609A2 (en) 2004-10-28
EP1631281B1 (en) 2012-05-09
ES2403283T3 (es) 2013-05-17
EP2340831B1 (en) 2014-09-10
EP2116240B1 (en) 2013-02-27
EP1631281A2 (en) 2006-03-08
ES2509093T3 (es) 2014-10-17

Similar Documents

Publication Publication Date Title
HK1087351A1 (en) Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
WO2005048948A3 (en) Urea derivatives as kinase modulators
IL175055A0 (en) Combinations useful for the treatment of neuronal disorders
PL1765388T3 (pl) Terapia skojarzona do zapobiegania chorobie Alzheimera lub leczenia tej choroby oraz zestaw do tego celu
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
HK1152243A1 (en) Vegf for use in the treatment of central nervous system disorders vegf
MXPA03007960A (es) Compuestos y metodos para el tratamiento de desordenes urogenitales.
GB0117645D0 (en) Therapeutic stratergies for prevention and treatment of alzheimers disease
HK1086027A1 (en) Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
IL225192A (en) Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
PT1687284E (pt) Inibidores de quinase p-38
EP1535971A4 (en) TREATED PIGMENT, ITS USE, AND COMPOUND FOR THE TREATMENT OF PIGMENTS
EP1809369A4 (en) MEDICAL DEVICES FOR DETECTION, PREVENTION AND / OR TREATMENT OF NEUROLOGICAL DISEASES AND RELEVANT PROCEDURES
DK1355669T3 (da) Forbedret kognitiv træning
WO2007028151A3 (en) Surgical devices and related methods thereof
DK1408976T5 (da) Behandling af ADHD (Attention deficit hyperactivity disorder)
BRPI0417108A (pt) métodos de tratamento de rejeições de transplantes em pacientes
HK1080408A1 (en) Use of brimonidine in the treatment of dementia a nd parkinson
AU2003215190A8 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
MXPA05002418A (es) Derivados de 1,4-pirazina sustituidos.
DE602004013540D1 (de) Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen
GB2388027B (en) Use of palatinose for the treatment of mental stress
EP1601799A4 (en) METHODS AND COMPOSITIONS FOR TREATING AIDS AND HIV-ASSOCIATED DISEASES USING 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735 , 1786, 10220, 17822, 33945, 43748, 47161, 81982, OR 46777
WO2004058154A3 (en) Method of identifying therapeutic agents
WO2005018563A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190405